Impact of chronic kidney disease on use of evidence-based therapy in stable coronary artery disease: A prospective analysis of 22,272 patients

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Kalra, Paul R ^a,b   García Moll, Xavier ^c   Zamorano, José ^d   Kalra, Philip A ^e   Fox, Kim M ^b,f   Ford, Ian ^g   Ferrari, Roberto ^h   Tardif, Jean Claude ⁱ   Tendera, Michal ^j   Greenlaw, Nicola ^g   Steg, Ph Gabriel ^f,k,l,m  

^a PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^f ROYAL BROMPTON HOSPITAL   (United Kingdom)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

^h UNIVERSITY HOSPITAL OF FERRARA   (Italy)

ⁱ MONTREAL HEART INSTITUTE   (Canada)

^j MEDICAL UNIVERSITY OF SILESIA   (Poland)

^k UNIVERSITÉ PARIS DESCARTES   (France)

^l Site Xavier Bichat and Département Hospitalo Universitaire Fibrosis Inflammation and Remodeling   (France)

^m BICHAT HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CARDIOVASCULAR AGENT;

ADULT; AGE; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG USE; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCRIPTION; PREVALENCE; PROPHYLAXIS; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE; AGED; CHRONIC KIDNEY FAILURE; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; EVIDENCE-BASED MEDICINE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84904661860     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102335     Document Type: Article

References (21)

1. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, et al. (2004) Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351: 1285-1295. (Pubitemid 39258422)
2. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, et al. (2012) Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 380: 807-814.
3. Latif F, Kleiman NS, Cohen DJ, Pencina MJ, Yen CH, et al. (2009) In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. JACC Cardiovasc Interv 2: 37-45.
4. Roghi A, Savonitto S, Cavallini C, Arraiz G, Angoli L, et al. (2008) Impact of acute renal failure following percutaneous coronary intervention on long-term mortality. J Cardiovasc Med (Hagerstown) 9: 375-381. (Pubitemid 351374268)
5. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, et al. (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169. (Pubitemid 37337595)
6. Tripepi G, Mallamaci F, Zoccali C (2005) Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 16 Suppl 1: S83-88. (Pubitemid 41725091)
7. Krause MW, Massing M, Kshirsagar A, Rosamond W, Simpson RJ Jr (2004) Combination therapy improves survival after acute myocardial infarction in the elderly with chronic kidney disease. Ren Fail 26: 715-725. (Pubitemid 39579135)
8. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, et al. (2002) Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 137: 563-570.
9. Steg PG (2009) Heart rate management in coronary artery disease: the CLARIFY registry. Eur Heart J 11(suppl D): D13-D18.
10. Steg PG, Ferrari R, Ford I, Greenlaw N, Tardif JC, et al. (2012) Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PLoS One 7: e36284.
11. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, et al. (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612.
12. National Kidney F (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39: S1-266.
13. Arora P, Vasa P, Brenner D, Iglar K, McFarlane P, et al. (2013) Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey. CMAJ 185: E417-423.
14. Zachariah D, Brown R, Kanagala P, Bashir A, Mohan M, et al. (2014) The impact of age and chronic kidney disease on secondary prevention post-primary percutaneous coronary intervention. QJM 107: 185-192.
15. Centers for Disease Control and Prevention National Health and Nutrition Examination Survey. http://www.cdc.gov/nchs/nhanes.htm. Access date: 2014 March 7.
16. Eddington H, Sinha S, Li E, Hegarty J, Ting J, et al. (2009) Factors associated with vascular stiffness: cross-sectional analysis from the Chronic Renal Insufficiency Standards Implementation Study. Nephron Clin Pract 112: c190-198.
17. Choi JS, Kim CS, Bae EH, Ma SK, Jeong MH, et al. (2012) Suboptimal medical care of patients with ST-elevation myocardial infarction and renal insufficiency: results from the Korea Acute Myocardial Infarction Registry. BMC Nephrol 13: 110.
18. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, et al. (2010) Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation 121: 357-365.
19. Hanna EB, Chen AY, Roe MT, Saucedo JF (2012) Characteristics and in-hospital outcomes of patients presenting with non-ST-segment elevation myocardial infarction found to have significant coronary artery disease on coronary angiography and managed medically: stratification according to renal function. Am Heart J 164: 52-57 e51.
20. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, et al. (2013) Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 127: 224-232.
21. KDIGO (2012) CKD evaluation and management. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. http://kdigo.org/home/guidelines/ckd-evaluation-management/. Access date: 2014 March 7.